The FDA approved Itvisma gene therapy for patients aged 2 years and older with spinal muscular atrophy and confirmed SMN1 ...
Voyxact, an APRIL inhibitor, receives FDA accelerated approval for adults with primary IgA nephropathy to reduce proteinuria.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback